Top Markets
Coin of the day
Molecular Pharmacology (USA), Ltd. Molecular Pharmacology (USA), Ltd.

Molecular Pharmacology (USA), Ltd.

MLPH
株式のランク #39112
As a development-stage company, Molecular Pharmacology (USA) Limited (MLPH) is... As a development-stage company, Molecular Pharmacology (USA) Limited (MLPH) is dedicated to the creation and market introduction of solutions for pain and inflammation, with a primary focus on the Australian and United States markets. Through its subsidiary, Molecular Pharmacology Pty. Ltd., it is advancing an analgesic and anti-inflammatory molecule called Tripeptofen, designed to alleviate common daily pain. These products are offered in diverse dosage forms, formulations, and packaging options to suit various needs. MLPH's marketing strategy involves leveraging pharmaceutical distributors and forging collaborative partnerships with companies in the United States and Europe. Additionally, the company maintains an agreement with Dermatology Development Corporation to jointly develop and market a suite of therapeutic, cosmetic, and cosmeceutical items derived from the ThermaLIFE product line and its core active component. Headquartered in Perth, Australia, Molecular Pharmacology (USA) Limited operates as a subsidiary of PharmaNet Group Limited.
株価
$0.0322
最終同期: 2026-08-11
時価総額
$643.71K
変化(1日)
0.00%
変化(1年)
544.00%
AU
取引 Molecular Pharmacology (USA), Ltd. (MLPH)

カテゴリー

Molecular Pharmacology (USA), Ltd.(MLPH)の利益
2026 時点の利益 TTM: 0
Molecular Pharmacology (USA), Ltd. の最新の財務報告によると、同社の現在の利益は 0 です。2026 年には 0 の利益を上げ、これは 2026 年の利益 0 と 同等 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Molecular Pharmacology (USA), Ltd. の利益の推移(2026 〜 2026)
各年末の利益
利益 変化
提供された日付のデータは十分ではありません。
同業他社の利益